![Sample our Social Sciences journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110822/TOC-Subject-Sample-2021-Social-Sciences.jpg"})
Abstract
This paper identifies and explores some of the major current policy developments in the EU pharmaceutical environment. The policies considered are: the new pan‐EU drug licensing system; changes to the rules of the system over time; the BSE crisis as it affects Pharmaceuticals; member states' pricing and reimbursement policies and the EU Directive; companies calling government policy into account; governments calling companies policies into account; and the new working parties addressing issues on a single EU pharmaceutical market.